Methods and compositions related to neuroactive thiazoline compounds
In one aspect, the invention relates to compounds having a general structure: and methods of using same to modulate calcium release. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
1. A method for treating a disorder in a mammal, the method comprising the step of administering to the mammal an effective amount of least one compound having a structure represented by a formula:
wherein ----- is an optional covalent bond, wherein valency is satisfied;
wherein Z is selected from O and S;
wherein R 1 is selected from hydrogen and optionally substituted C1-C6 alkyl;
wherein R 2 is selected from nitrile, formyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfonyl, thioamido, amino-carbonyl, and alkylamine-carbonyl;
wherein R 3 is selected from hydrogen and optionally substituted C1-C6 alkyl;
wherein each of R 4a , R 4b ,R 4c , and R 4d is independently selected from hydrogen, halogen, hydroxyl, nitrile, nitro, thiol, formyl, optionally substituted amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkyl sulfonyl, optionally substituted alkylamino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, alkylamine-carbonyl, and optionally substituted C1-C6 alkyl;
or a pharmaceutically acceptable salt thereof,
wherein the disorder is asthma.
2. The method of claim 1 , wherein the mammal is a human.
3. The method of claim 1 , wherein the mammal has been diagnosed with a need for treatment of the disorder prior to the administering step.
4. The method of claim 1 , wherein Z is S.
5. The method of claim 1 , wherein R 1 is methyl.
6. The method of claim 1 , wherein R 2 is selected from formyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, alkoxycarbonyl, amino-carbonyl, and alkylamine-carbonyl.
7. The method of claim 1 , wherein R 2 has a structure represented by a formula:
wherein Y is selected from O and S;
wherein R 5a and R 5b together comprise ═O or ═S, or wherein each of R 5a and R 5b is independently selected from hydrogen and optionally substituted C1-C6 alkyl;
wherein R 6 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted benzyl.
8. The method of claim 1 , wherein R 3 is hydrogen.
9. The method of claim 1 , wherein the compound has a structure represented by a formula:
wherein R 1 is selected from hydrogen and optionally substituted C1-C6 alkyl;
wherein R 2 is selected from nitrile, formyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkyl sulfonyl, thioamido, amino-carbonyl, and alkylamine-carbonyl;
or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 , wherein the compound is selected from:
11. The method of claim 1 , wherein the compound has a structure represented by a formula:
12. A method for treating a disorder in a mammal, the method comprising the step of administering to the mammal an effective amount of least one compound having a structure represented by a formula:
wherein Z is selected from O and S;
wherein R 1 is optionally substituted C1-C6 alkyl;
wherein R 2 is selected from nitrile, formyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkyl sulfonyl, thioamido, carboxamide, amino-carbonyl, and alkylamine-carbonyl;
wherein R 3 is selected from hydrogen and optionally substituted C1-C6 alkyl;
or a pharmaceutically acceptable salt thereof,
wherein the disorder is asthma.
13. The method of claim 12 , wherein the mammal is a human.
14. The method of claim 12 , wherein the mammal has been diagnosed with a need for treatment of the disorder prior to the administering step.
15. The method of claim 1 , wherein Z is S.
16. The method of claim 1 , wherein R 1 is methyl.
17. The method of claim 1 , wherein R 2 is selected from formyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl.
18. The method of claim 1 , wherein R 2 has a structure represented by a formula:
wherein Y is selected from O and S;
wherein R 5a and R 5b together comprise ═O or ═S, or wherein each of R 5a and R 5b is independently selected from hydrogen and optionally substituted C1-C6 alkyl;
wherein R 6 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted benzyl.
19. The method of claim 12 , wherein R 3 is hydrogen.
20. The method of claim 12 , wherein the compound has a structure represented by a formula:
wherein R 1 is optionally substituted C1-C6 alkyl;
wherein R 2 is selected from nitrile, formyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfonyl, thioamido, carboxamide, amino-carbonyl and alkylamine-carbonyl;
or a pharmaceutically acceptable salt thereof.
21. The method of claim 12 , wherein the compound is selected from:
22. The method of claim 12 , wherein the compound has a structure represented by a formula:
23. A method for treating a disorder in a mammal, the method comprising the step of administering to the mammal an effective amount of least one compound having a structure represented by a formula:
wherein Z is selected from O and S;
wherein R 2 is selected from nitrile, formyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkyl sulfonyl, thioamido, alkoxycarbonyl, amino-carbonyl, and alkylamine-carbonyl;
or a pharmaceutically acceptable salt thereof,
wherein the disorder is asthma.
24. The method of claim 23 , wherein R 2 is —CH 2 OH.